Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
 - EconoTimes)
NEW YORK, Feb. 19, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Cardiovascular Systems, Inc. (“Cardiovascular Systems” or the “Company”) (Nasdaq:CSII) in the United States District Court for the Central District of California on behalf of a class consisting of all persons or entities who purchased Cardiovascular Systems securities between September 12, 2011 and January 21, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period. According to the Complaint, on January 21, 2016, the Company disclosed during aftermarket hours that it expects revenue from its 2016 fiscal second quarter to be $41.4 million, a 4% decrease from the second quarter of fiscal 2015, and 3% below the guidance range due to the continued effects of the sales force transition. Similarly, like the financial results disclosed on October 7, 2015, the Company reported disappointing financial results due to the continued reformation of its sales force, which was a materialization of the Company’s receipt of the letter from the U.S. Attorney’s Office for the Western District of North Carolina stating that it is investigating the Company to determine whether the Company has violated the False Claims Act.
On this news, the market price of the Company’s common stock dropped almost 30%, closing at $8.74 per share on January 22, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than April 12, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
